Industry News (Clinical Trials)

Trial For Ovarian Cancer With Ovarex Therapeutic Vaccine Proceed

Published in Cancer Weekly, June 9th, 1997

AltaRex Corp., Edmonton, Alberta, Canada, announced that the U.S. Food and Drug Administration has allowed the company to proceed with its Investigational New Drug (IND) for the Phase IIb immunotherapeutic use of Ovarex Therapeutic Vaccine.

The company also announced that it will begin enrolling patients in a U.S. Phase IIb clinical trial of this anti-idiotype induction (AIT) vaccine for the adjuvant treatment of patients with advanced ovarian cancer.

The trial is a multicentre, placebo-controlled, double-blind, randomized adjuvant treatment study designed to test the safety and efficacy of AIT with the Ovarex therapeutic vaccine compared with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry